The Food and Drug Administration authorized the first autonomous robotic device capable of performing blood draws without requiring a trained phlebotomist on Aug. 19, marking a milestone in the deployment of robotic technology in routine clinical care.
The device uses imaging technology to locate veins and execute blood draws — a task that has historically required human skill and training — and could change staffing requirements in clinical labs, hospitals and outpatient settings across the country.
The authorization could improve access to blood draw services in rural and underserved areas where trained phlebotomists are in short supply, the FDA said. Blood draws are among the most common clinical procedures in American health care, with hundreds of millions performed annually.
The device was cleared through the FDA’s De Novo regulatory pathway, which is used for novel devices that have no existing predicate on the market. The authorization establishes a new regulatory category for autonomous clinical procedure devices.
For patients, robotic blood draws could reduce wait times, minimize failed draw attempts and expand the locations where blood collection is available. Patients in rural clinics, nursing homes and mobile health settings often face delays because phlebotomists are not on site.
The authorization follows the FDA’s broader regulatory momentum on artificial intelligence and robotic medical devices, which has accelerated in recent years as the agency has cleared hundreds of AI-enabled diagnostic and treatment tools.
Clinical laboratory professionals have raised questions about how robotic devices will integrate with existing workflows, liability frameworks and quality assurance protocols. The American Society for Clinical Laboratory Science has called for clear guidance on how facilities should deploy autonomous clinical devices.
The device’s manufacturer was not specified in the FDA’s announcement. The agency said it evaluated the device’s safety and effectiveness data before granting authorization.